Navigation Links
Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer

LUND, Sweden, March, 9, 2007-Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer.

By step-wise dose escalation, a safe dose of 1 mg/day of TASQ was achieved, which corresponds to a doubling of the previously reported maximum tolerated dose (MTD) level of 0.5 mg/day. This means that a step-wise intra-patient dose-escalation enables a dose of 1 mg/day to be administered in future clinical trials.

"These new results confirm and reinforce earlier results obtained at a lower dose level. We now have a very complete data set that constitute a solid base to move into Phase II clinical trials", said Sven Andréasson, President and CEO of Active Biotech.

The ongoing 10-week study comprises patients with so called hormone-refractory prostate cancer. This is an advanced stage of prostate cancer where the tumor cells no longer respond to hormone treatment. All patients entering the study had rising serum levels of Prostate Specific Antigen (PSA), which is a surrogate marker for tumor progression.

PSA measurements were recorded and PSA velocity (PSAV) was calculated after 28 days of treatment. Five out of six patients had a >50% decrease in PSA velocity compared to prior treatment. Three of these five patients exhibited a decrease in absolute PSA levels.

The study is being performed at the urological clinics at the University Hospitals in Lund, Malmö and Uppsala, Sweden.

The objective of the TASQ project is to develop a pharmaceutical product that can be administered orally for the long-term treatment of prostate cancer. Phase II studies are scheduled to start during 2007. The Medical Products Agency has approved on the new MTD to be used in the continued clinical program of TASQ.

The pharmaceutical market for prostate cancer is estimated at more than USD 3 billion a year. Prostat
'"/>




Page: 1 2

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

Post Your Comments:
(Date:12/1/2009)... Sleep Solutions®, Inc. (SSI),...testing and evaluation of sleep-disordered breathi...M.D., as its chief executive officer. Hassett was...ing its growth from a $250 million healthcare hold... total population health, and its subsequent sale ...
(Date:12/1/2009)...wswire/ -- At this year,s annual meeting of the Ra...Philips Electronics ( PHG, AEX: PHI) will introduc...s that provides radiologists the ability to review...elp drive quality and efficiency. Showcasing its ...ight new capabilities for its portfolio of diagnos...
(Date:12/1/2009)... Exagen Diagnostics, Inc., a molec...ps and markets proprietary genomic tests, today an... of the company,s board of directors and chief exe...nn was managing partner of Windamere Venture Partn...al companies including Prometheus Laboratories, Sa...
Breaking Medicine Technology:Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 4Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 2The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit 3B State Investigation Finds Evidence of Negligence at Woodbridge Day School 60768 1The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit 3B State Investigation Finds Evidence of Negligence at Woodbridge Day School 60768 2Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co Biomaster Inc 60766 1Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co Biomaster Inc 60766 2Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co Biomaster Inc 60766 3Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co Biomaster Inc 60766 4Qualsecs Wholly Owned Subsidiary Receives Order From New Jersey Based DMC Athletics and Rehabilitation 60764 1Qualsecs Wholly Owned Subsidiary Receives Order From New Jersey Based DMC Athletics and Rehabilitation 60764 2
...orporated (Nasdaq: VICL ),today is presenting exp...strating that the company,s Vaxfectin(R) adjuvant ...d infectious disease vaccines and,peptide-based ca...Vical,s,Senior Vice President of Product Developme... 8, at the World Vaccine Congress (Lyon, France - ...
...ealth Care and its Great,Lakes Cancer Institute ar...nds to share the latest work underway around the g...nts. The October 11th symposium, hosted by,McLaren..., M.D., an,award-winning surgical oncologist whose...er has gained worldwide recognition and has evolve...
Other Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2
(Date:12/1/2009)...est rates seen in Central and South America, study...ws) -- About 50 percent of intensive care unit pat...their risk of dying in the hospital, a new study f...a single day (May 8, 2007) on 13,796 patients, age...y found that 51 percent of patients were classifie...
(Date:12/1/2009)...ILADELPHIA (December 1, 2009) Wistar Institute r...f Pennsylvania and New York University have identi...cate early-stage lung tumors in people at high ris...hed online December 1 in Cancer Research , a jour...h, could lead to a simple blood test to detect lun...
(Date:12/1/2009)... , RESEARCH TRIANGLE PARK, N.C., Dec. 1 /P...itiated in 2001 and have expanded over the years s...lly. The facility which was originally set up in a...armacy services, as part of the suite of services ... industry as a valuable offering. ,, The pharma...
(Date:12/1/2009)... , WASHINGTON, Dec. 1 /PRNewswire-USNewswire...CDHPs) are more likely than those with traditional...haviors, to be more engaged in wellness programs, ...centives matter in holding down costs, according t... Employee Benefit Research Institute (EBRI). ,...
(Date:12/1/2009)... , FORT LAUDERDALE, Fla., Dec. 1 /PRNewswir... patient enrollment in the randomized clinical tri...tent (Combo Stent). ,, A prospective, randomize... valuation of an ablu M inal sirolimus coat ED ...tients at up to 20 sites in Asia, Australia, Europ...
Breaking Medicine News(10 mins):Health News:Half of ICU Patients Suffer From Infections 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4
...l elections in US. The issue is raging in neighbou...ticians to get away with glib talk. As the country...quent on the governments commitment to medicare, a...s need a credit card'' and "Where did medicare go?...
...nxiously awaiting reports later this week on wheth...e deadly viral hemorrhagic septicemia. Of...rces (DNR) confirmed that two fish from an adjoini...ke Butte des Morts is the first occurrence of the ...
...pressed over the housing together of two convicted...rs Robbie Sebastian Wheeler, 43, and his boyfrien...ether in Hakea jail, in West Australia. The t...ed to murder the boy and dispose of his body. ...
...rculosis, researchers say. A study of 131 ...ity of the body to inhibit the growth of the bacte...f BBC News. Until now no study has evaluat...cipants and infected with mycobacteria. Th...
...udents with asthma who participated in a specially...ported fewer days and nights with symptoms, fewer...vity, and less hospitalization for asthma during a...gist for the Henry Ford Health System in Detroit, ...
...stroke in the past two months across Orissa, offic... been reported from the southern district of Ganja...icts of Balasore, Kandhamal, Kendrapada, Nuapada a... from various parts of the state. These are being ...
Other Medicine News:Health News:Cancer Patients Turn Their Backs on Canadian Health Minister 2Health News:Deadly Virus Hits Popular Lake in US 2Health News:Outrage Against Gay PartnersInCrime Kept Together 2Health News:Web-based Asthma Program Improves Disease Management for Black Students 2
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: